Loading...

Home
ETF
HALO

HALO

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

HALO News

Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook

May 12 2026seekingalpha

Halozyme (HALO) Q1 2026 Earnings Transcript

May 12 2026NASDAQ.COM

FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis

May 09 2026seekingalpha

Halozyme Therapeutics Q1 Earnings Announcement Scheduled

May 08 2026seekingalpha

Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement

May 07 2026seekingalpha

Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets

May 07 2026PRnewswire

HALOZYME AND GSK ENTER INTO GLOBAL PARTNERSHIP AND LICENSE DEAL TO ADVANCE SUBCUTANEOUS FORMULATIONS FOR SEVERAL PROMISING CANCER TARGETS

May 07 2026moomoo

Halozyme to Release Q1 2026 Financial Results on May 11

Apr 30 2026PRnewswire

Halozyme Appoints New CFO Darren Snellgrove

Apr 30 2026NASDAQ.COM

Halozyme Appoints New Chief Financial Officer

Apr 30 2026PRnewswire

Halozyme and Vertex Enter Exclusive Licensing Agreement

Apr 07 2026seekingalpha

Halozyme Enters Exclusive Collaboration with Vertex Pharmaceuticals

Apr 07 2026PRnewswire

Halozyme Appoints Interim CFO David Ramsay

Mar 12 2026seekingalpha

Halozyme Appoints New Interim CFO David Ramsay

Mar 12 2026PRnewswire

Halozyme Appoints New Interim CFO David Ramsay

Mar 12 2026Newsfilter

Halozyme and Johnson & Johnson's Combination Therapy Approved

Mar 06 2026NASDAQ.COM